Aveanna Healthcare Holdings (AVAH) Earnings Date & Reports

Key Takeaways

• Aveanna Healthcare Holdings (AVAH) is expected to report its third-quarter fiscal 2026 results on November 5, 2026, before the market opens.
• Wall Street consensus points to adjusted earnings per share (EPS) of roughly $0.20 on revenue of approximately $679 million, up from $0.15 EPS and $621.9 million in the prior-year period.
• The company has beaten consensus EPS in seven of its last eight quarters, most recently posting $0.22 versus a $0.17 estimate.
• Management raised full-year 2026 guidance in August to revenue above $2.68 billion and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) above $365 million.
• Investors will be watching preferred-payer momentum, caregiver labor trends, and the timing of margin effects tied to an upcoming California private duty nursing (PDN) rate increase.

Earnings Context and Why It Matters

Aveanna Healthcare is a diversified home care platform serving medically complex, high-cost patients across three segments: Private Duty Services, Home Health and Hospice, and Medical Solutions. After several years of reimbursement-rate and caregiver labor pressures, the company has returned to consistent growth, with second-quarter revenue rising 13.7% year over year to $670.5 million and full-year guidance raised. The third-quarter report matters because it tests whether that momentum can hold while the company invests in caregiver wages ahead of a California PDN rate increase effective January 1, 2027. For investors, the print offers a timely read on demand for home and community-based care, margin durability, and the pace of deleveraging.

Earnings Expectations

Analysts expect Aveanna to report adjusted EPS of about $0.20 for the third quarter of fiscal 2026, with individual estimates generally ranging from roughly $0.19 to $0.21. Consensus revenue is approximately $679 million, which would represent growth of about 9% from the $621.9 million reported in the same period a year earlier, when the company earned $0.15 per share.

Aveanna does not provide quarterly EPS guidance, and management has said it does not guide net income because of volatility tied to interest rate derivative valuations. Instead, the company's outlook is anchored to its full-year 2026 targets, which were raised in August to revenue above $2.68 billion and adjusted EBITDA above $365 million. Key operating metrics investors will scrutinize include Private Duty Services revenue per hour, the Home Health episodic mix (the share of admissions reimbursed on a bundled, episodic basis), preferred-payer agreement counts, and unique patients served in Medical Solutions.

The company's track record heading into the print is strong: it has topped consensus EPS in seven of the past eight quarters, and shares jumped roughly 18% in pre-market trading after the second-quarter beat in August.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following home healthcare names like Aveanna, it offers a structured way to surface comparable opportunities and monitor sector momentum. Explore the AI Screener to refine your market research.

Market Reaction and Investor Sentiment

Sentiment heading into Aveanna's third-quarter report has been broadly positive. The stock has climbed since the August earnings release, supported by the raised guidance, improving reimbursement trends, and a run of estimate beats. Several sell-side firms lifted their price targets following the second-quarter results, reflecting growing confidence in the preferred-payer strategy and in the long-term growth outlook for the Private Duty Services and Home Health and Hospice segments.

That optimism, however, carries a higher bar. Key risks ahead of the report include near-term margin pressure from proactive caregiver wage investments made before the California rate increase takes effect, ongoing labor availability constraints, and acquisition integration costs tied to the Family First Homecare deal. Any sign that adjusted EBITDA margins are compressing faster than expected, or that volume growth is moderating, could temper the stock's recent run.

Forward Outlook and Key Factors to Monitor

The most important near-term catalyst is the California pediatric private duty nursing rate increase, which takes effect January 1, 2027. Management has said it plans to raise nurse wages during the fall to recruit and retain caregivers ahead of that change, meaning the third and fourth quarters could absorb wage costs before the higher reimbursement rates begin flowing through. Investors should monitor how this timing affects Private Duty Services margins and the company's "spread" between revenue and cost per hour.

Integration of the Family First Homecare acquisition, which closed in early June, is another area to watch. Management expects to complete the majority of that integration by late in the fourth quarter, and progress here will influence both cost trends and capacity growth in Florida and surrounding markets.

On the regulatory front, Aveanna has pointed to a more stable rate environment, including the proposed 2027 Medicare Home Health rule and the final Hospice rule. Favorable outcomes there would support the Home Health and Hospice segment's updated long-term organic growth target of 8% to 10%. The company also expects Medical Solutions growth to remain in the high single digits for a few more quarters before re-accelerating to double digits in early 2027.

Finally, balance sheet progress remains a theme. Aveanna generated positive free cash flow in the first half of 2026, repriced its term loan to reduce annual interest expense, and continues to target a sub-3x net leverage ratio. Investors will look for continued deleveraging and free cash flow generation as indicators that the company can fund growth while strengthening its financial position.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations